+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group



Natural history of myocardial infarction in the coronary drug project: long-term prognostic importance of serum lipid levels. Coronary Drug Project Research Group



American Journal of Cardiology 42(3): 489-498



The relation between baseline fasting serum lipid levels (serum cholesterol and triglycerides) and 5 year rates for four end points--mortality from all causes, mortality from coronary heart disease, sudden death due to coronary heart disease and incidence of nonfatal myocardial infarction plus coronary death--was studied in 2,789 men. These were patients in the Coronary Drug Project placebo group who were 30 to 64 years old on entry and had recovered from one or more previous documented myocardial infarctions. Serum cholesterol was significantly related to all four end points, in both univariate and multivariate regression analyses (with control of 38 or 39 other factors in the latter). This significant relation of cholesterol to these end points was shown at low, medium and high levels of serum triglycerides. In contrast, baseline fasting serum triglyceride levels were not positively related to any of these end points. In these postmyocardial infarction patients, findings indicative of cardiovascular status at baseline evaluation, particularly the state of the myocardium, were more powerful prognosticators than serum cholesterol. These findings underscore the importance of efforts to prevent the first coronary episode. They also indicate the possibility after recovery from acute myocardial infarction of improving long-term prognosis through reduction of serum cholesterol.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040775250

Download citation: RISBibTeXText

PMID: 356579


Related references

Treatable risk factors--hypercholesterolemia, smoking, and hypertension--after myocardial infarction: implications of the coronary drug project data for clinical management. Coronary Drug Project Research Group. Primary Care 7(1): 175-179, 1980

The natural history of coronary heart disease prognostic factors after recovery from myo cardial infarction in the coronary drug project. Circulation Supplement: Ii-193, 1978

Cigarette smoking as a risk factor in men with a prior history of myocardial infarction. The Coronary Drug Project Research Group. Journal of Chronic Diseases 32(6): 415-425, 1979

The natural history of coronary heart disease prognostic factors after recovery from myo cardial infarction in 2789 men 5 year findings of the coronary drug project. Circulation 66(2): 401-414, 1982

The prognostic importance of the electrocardiogram after myocardial infarction. Experience in the Coronary Drug Project. Annals of Internal Medicine 77(5): 677-689, 1972

Implications of findings in the coronary drug project for secondary prevention trials in coronary heart disease. The coronary; drug project research group. Circulation 63(6): 1342-1350, 1981

Prognostic importance of premature beats following myocardial infarction. Experience in the coronary drug project. JAMA 223(10): 1116-1124, 1973

The natural history of myo cardial infarction in the coronary drug project prognostic indicators following infarction. TIBBLIN, GOSTA, ANCEL KEYS AND LARS WERKO (ED ) PREVENTIVE CARDIOLOGY PROCEEDINGS OF AN INTERNATIONAL SYMPOSIUM BILLINGEHUS, SKOEVDE, SWEDEN, AUG 21, 1971 181P ILLUS MAP ALMQVIST and WIKSELL: STOCKHOLM, SWEDEN; HALSTED PRESS, A DIVISION OF JOHN WILEY and SONS: NEW YORK, N Y , U S A 54-64, 1972

Practical aspects of decision making in clinical trials: the coronary drug project as a case study. The Coronary Drug Project Research Group. Controlled Clinical Trials 1(4): 363-376, 1981

The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA 220(7): 996-1008, 1972

The Coronary Drug Project: methods and lessons of a multicenter clinical trial. Coronary Drug Project Research Group. Controlled Clinical Trials 4(4): 1-541, 1983

The coronary drug project aspirin study. Implications for clinical care. Coronary Drug Project Research Group. Primary Care 5(1): 91-95, 1978

Blood pressure in survivors of myocardial infarction. The Coronary Drug Project Research Group. Journal of the American College of Cardiology 4(6): 1135-1147, 1984

The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. The coronary Drug Project Research Group. JAMA 226(6): 652-657, 1973

Factors influencing long-term prognosis after recovery from myocardial infarction--three-year findings of the coronary drug project. Journal of Chronic Diseases 27(6): 267-285, 1974